10-K: The Cannabist Company Holdings Inc. Reports Fiscal Year 2024 Results, Announces Debt Restructuring

The Cannabist Company Holdings Inc. announces its fiscal year 2024 results and a debt restructuring plan to extend maturities and improve financial flexibility.

Summary

• The Cannabist Company Holdings Inc. reported its financial results for the fiscal year ended December 31, 2024.
• The company has entered into a support agreement with certain noteholders to restructure its debt, aiming to extend maturity dates and enhance financial stability.
• The company's common shares are listed on the Cboe Canada under the symbol CBST and are quoted on the OTCQX Best Market under the symbol CBSTF.
• The company, through its subsidiaries, currently owns or manages interests in several state-licensed medical and/or adult use marijuana businesses in California, Colorado, Delaware, Illinois, Maryland, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, Virginia, and West Virginia.
• The company has exited its prior operations in Florida, Missouri, Utah, Washington D.C., the European Union and Puerto Rico.
• On January 15, 2025, the Company completed the sale of a non-operating facility in DE for gross proceeds of $3.4 million, and fully settled the outstanding mortgage on the property of $1.8 million.
• The company entered into a support agreement on February 27, 2025, with certain noteholders representing approximately 61% of the aggregate principal amount of issued Senior Notes regarding the exchange of their Senior Notes for new notes having a later maturity date and additional covenants.
• Holders of the 2025 Notes and the 2026 Notes will exchange their Senior Notes for an equal principal amount of 9.25% senior secured notes due December 31, 2028.
• The company will also issue 118,209,105 common shares, representing 24.99% of the issued and outstanding shares of the Company, on a pro rata basis to holders of Senior Notes who elect to receive New Senior Notes.
• Existing shareholders of the Company will be granted new common share purchase warrants to acquire an aggregate of 118,246,947 newly issued common shares, representing approximately 20% of the common shares on a pro forma, diluted basis.
• The Transaction will be subject to approval by the Ontario Superior Court of Justice pursuant to the Plan of Arrangement under the Canada Business Corporations Act.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is taking steps to restructure its debt and improve financial flexibility, it also reported a net loss and a decrease in revenue for the year ended December 31, 2024. The material weaknesses in internal control over financial reporting also raise concerns.

Positives

• The company is restructuring its debt to extend maturity dates and improve financial flexibility.
• The company completed the sale of a non-operating facility in DE for gross proceeds of $3.4 million, and fully settled the outstanding mortgage on the property of $1.8 million.

Negatives

• The company reported a net loss of $105.1 million for the year ended December 31, 2024.
• The company's revenue decreased by 10% to $458.7 million for the year ended December 31, 2024.
• The company's disclosure controls and procedures were not effective as of December 31, 2024 due to material weaknesses in its internal control over financial reporting.

Risks

• The completion of the Plan of Arrangement may not occur or may be delayed.
• The Support Agreement may be terminated.
• If the Plan of Arrangement is not completed, the market price or value of the Senior Notes and/or of the Common Shares may decline.
• The uncertainty surrounding the Plan of Arrangement could negatively impact the Company's current and future operations, financial condition and prospects.
• The pending Plan of Arrangement may divert the attention of the Company's management.
• Despite the Company's current level of indebtedness, the Company may be able to incur more debt following completion of the Plan of Arrangement.
• The Plan of Arrangement may have adverse tax consequences on the Company.
• Following the Plan of Arrangement, the Company may not be able to generate sufficient cash to service all of its indebtedness, including the New Notes, and may be forced to take other actions to satisfy its obligations under its indebtedness, which may not be successful.
• Marijuana remains illegal under federal law, and enforcement of cannabis laws could change.
• There is no guarantee that the Rohrabacher-Farr Amendment will be renewed.
• There is a risk of civil asset forfeiture of the Company's assets.
• The Company is subject to anti-money laundering laws and regulations.
• U.S. border officials could deny entry into the U.S. to employees of, or investors in companies with cannabis operations in the United States.
• The Company may lack access to U.S. bankruptcy protections.
• The Company may face heightened scrutiny by regulatory authorities.
• Residents of the United States may be unable to settle trades of the Company's securities.
• The cannabis industry may experience legal, regulatory or political change.
• The Company may have difficulty accessing the services of banks, which may make it difficult to operate its business.
• The Company may have difficulty accessing public and private capital.
• The Company may face unfavorable publicity or consumer perception.
• The results of future clinical research may have a material adverse effect on the Company.
• Expansion into the adult-use cannabis market may subject the Company to additional regulation.
• The Company's business is subject to a variety of laws, regulations and guidelines.
• The Company may face penalties for regulatory violations
• The Company may face risks related to FDA and FTC enforcement.
• Cannabis businesses are subject to unfavorable tax treatment as a result of Section 280E.
• The Company's service providers may suspend or withdraw their services.
• The Company may be unable to enforce its contracts.
• Ability to grow the Company's business depends on state laws pertaining to the cannabis industry.
• Reliable data on the cannabis industry is not available.
• Conversions and potential future sales of shares could adversely affect prevailing market prices for the common shares.
• Additional issuances of Common Shares, Proportionate Voting Shares, and Preferred Shares may result in dilution.
• The Company's Articles provides that the Supreme Court of the Province of British Columbia, Canada and the appellate Courts therefrom are the sole and exclusive forum for any derivative action brought on behalf of the Company, which may limit our investors flexibility in selecting a forum for any future disputes.
• The Company may grow low quality cannabis.
• The Company faces risks inherent in the agricultural business.
• Climate change could exacerbate certain of the risks inherent in the Company's agricultural operations.
• The Company may face risks related to its third-party product manufacturers.
• The Company is exposed to product liability claims.
• The Company's products may be subject to product recalls.
• Significant failure or deterioration of the Company's quality control systems could have a material adverse effect on the Company.
• The Company is subject to environmental risk and regulation.
• The Company has limited operating history.
• The Company had negative net losses during the fiscal year ended December 31, 2024.
• The Company's efforts to obtain needed capital resources and sources of liquidity may not be sufficient to support its business operations and future growth strategies.
• The Company faces intense competition from other companies.
• New well-capitalized entrants into the cannabis industry may develop large-scale operations.
• The Company is vulnerable to rising energy costs.
• The Company is reliant is on key inputs.
• The Company is reliant on suppliers and skilled labor.
• The Company's sales are difficult to forecast.
• The Company faces intellectual property risks.
• The Company may not be able to protect its trademarks.
• The Company may infringe on intellectual property rights of third parties.
• The Company faces competition from synthetic production and technological advances.
• The Company may face constraints on marketing products.
• The Company may be exposed to risk of fraudulent or illegal activity by employees, contractors and consultants.
• Certain jurisdictions currently prohibit public company ownership of cannabis businesses.
• The Company depends on information technology systems and may experience cyber-attacks.
• A security breach may have a material adverse effect on the Company.
• We have been, and expect to continue to be, a target of cyberattacks. If our internal networks, systems, or data are or are perceived to have been compromised, our reputation may be damaged and our financial results may be negatively affected.
• The Company is subject to high bonding and may face difficulty obtaining insurance coverage.
• The Company may not pay dividends.
• The Company's use of customer information and other personal and confidential information may have an adverse impact.
• The Company is subject to taxation in both Canada and the United States.
• The Company may be subject to net operating loss and certain other tax attribute limitations.
• Dividends may be subject to Canadian and/or United States withholding tax.
• Transfers of Common Shares may be subject to United States gift, estate and transfer taxes.
• Changes in tax laws may affect the Company and its shareholders.
• Market price of the common shares may be highly volatile.
• Further equity financing may dilute the interests of the Company shareholders and depress the price of the common shares.
• Conflicts of interest may exist between the Company and its directors or officers.
• Certain remedies may be limited.
• We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern and it is possible that we may identify conditions and events in the future that raise substantial doubt about our ability to continue as a going concern.
• The Company is reliant on management.
• The Company may become party to litigation from time to time.
• The Company may be unable to manage its growth effectively.
• The Company is subject to significant costs of being a public company.
• The trading market for common shares is influenced by securities industry analyst research reports.
• Past performance may not be indicative of future results.
• Financial projections may prove materially inaccurate or incorrect.
• Global financial conditions may have an adverse impact on the Company.
• Disease outbreaks may negatively impact the Company.
• There may not be an active, liquid market for the Common Shares.
• Return on the Common Shares is not guaranteed.

Future Outlook

The company is targeting closing the debt restructuring transaction in the first half of 2025, subject to the satisfaction of closing conditions, including court approval of the Plan of Arrangement and the receipt of any necessary state cannabis regulatory approvals.

Industry Context

The announcement reflects the ongoing challenges and adjustments within the cannabis industry, including price compression, increased competition, and the need for financial restructuring to ensure long-term sustainability.

Comparison to Industry Standards

• The company's performance can be compared to multi-state operators (MSOs) like Curaleaf, Trulieve, and Green Thumb Industries, which also face similar challenges in the cannabis market.
• The debt restructuring is a common strategy in the cannabis industry, with companies like Canopy Growth and Aurora Cannabis also undertaking similar measures to manage their debt and improve financial flexibility.
• The company's focus on core markets and divestiture of non-core assets aligns with the strategies of other MSOs seeking to optimize their operations and improve profitability.

Stakeholder Impact

• Shareholders will be impacted by the debt restructuring, including the issuance of new common shares and warrants, which may dilute their ownership.
• Creditors will be impacted by the exchange of Senior Notes for new notes with different terms and maturity dates.
• Employees may be impacted by the company's cost-saving initiatives and strategic reassessment of its business.

Next Steps

• The company expects to call a meeting of holders of Senior Notes to approve the debt restructuring transaction.
• The company is targeting closing the debt restructuring transaction in the first half of 2025, subject to the satisfaction of closing conditions, including court approval of the Plan of Arrangement and the receipt of any necessary state cannabis regulatory approvals.

Key Dates